JP2022533958A5 - - Google Patents
Info
- Publication number
- JP2022533958A5 JP2022533958A5 JP2021568229A JP2021568229A JP2022533958A5 JP 2022533958 A5 JP2022533958 A5 JP 2022533958A5 JP 2021568229 A JP2021568229 A JP 2021568229A JP 2021568229 A JP2021568229 A JP 2021568229A JP 2022533958 A5 JP2022533958 A5 JP 2022533958A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- solvate
- acceptable salt
- deuterium
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962847519P | 2019-05-14 | 2019-05-14 | |
| US62/847,519 | 2019-05-14 | ||
| PCT/US2020/032725 WO2020232156A1 (en) | 2019-05-14 | 2020-05-13 | Compound for treating gout or hyperuricemia |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533958A JP2022533958A (ja) | 2022-07-27 |
| JP2022533958A5 true JP2022533958A5 (enExample) | 2023-05-15 |
| JP7656548B2 JP7656548B2 (ja) | 2025-04-03 |
Family
ID=73288915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568229A Active JP7656548B2 (ja) | 2019-05-14 | 2020-05-13 | 痛風または高尿酸血症を処置するための化合物 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20220242841A1 (enExample) |
| EP (1) | EP3968989A4 (enExample) |
| JP (1) | JP7656548B2 (enExample) |
| KR (1) | KR102971948B1 (enExample) |
| CN (1) | CN113874014A (enExample) |
| AU (2) | AU2020274165A1 (enExample) |
| BR (1) | BR112021022843A2 (enExample) |
| CA (1) | CA3140412A1 (enExample) |
| IL (1) | IL288034B2 (enExample) |
| MA (1) | MA55973A (enExample) |
| MX (1) | MX2021013980A (enExample) |
| SG (1) | SG11202112562XA (enExample) |
| TW (1) | TW202108561A (enExample) |
| WO (1) | WO2020232156A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164439A (zh) | 2018-12-06 | 2021-07-23 | 安索治疗公司 | 用于治疗或预防痛风或高尿酸血症的方法 |
| JP2022511800A (ja) | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| KR20230024354A (ko) * | 2020-06-10 | 2023-02-20 | 아쓰로시 테라퓨틱스, 인크. | 만성 신장 질환을 치료 또는 예방하는 방법 |
| WO2023058975A1 (ko) * | 2021-10-07 | 2023-04-13 | (주)이노보테라퓨틱스 | 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물 |
| WO2023098872A1 (en) * | 2021-12-02 | 2023-06-08 | Arthrosi Therapeutics, Inc. | Crystalline forms of a compound for treating or preventing gout or hyperuricemia |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
| US20250242050A1 (en) | 2024-01-31 | 2025-07-31 | The Industry & Academic Cooperation In Chungnam National University (Iac) | Composition for treating gout containing cyclodextrin-conjugated polymer nano-drug and method for treating gout |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| AU2017298142B2 (en) * | 2016-07-18 | 2021-11-11 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| JP2022511800A (ja) * | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス，インク． | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
-
2020
- 2020-05-13 CA CA3140412A patent/CA3140412A1/en active Pending
- 2020-05-13 JP JP2021568229A patent/JP7656548B2/ja active Active
- 2020-05-13 SG SG11202112562XA patent/SG11202112562XA/en unknown
- 2020-05-13 US US17/610,673 patent/US20220242841A1/en not_active Abandoned
- 2020-05-13 MA MA055973A patent/MA55973A/fr unknown
- 2020-05-13 KR KR1020217041035A patent/KR102971948B1/ko active Active
- 2020-05-13 AU AU2020274165A patent/AU2020274165A1/en not_active Abandoned
- 2020-05-13 BR BR112021022843A patent/BR112021022843A2/pt unknown
- 2020-05-13 EP EP20804806.6A patent/EP3968989A4/en active Pending
- 2020-05-13 MX MX2021013980A patent/MX2021013980A/es unknown
- 2020-05-13 CN CN202080035809.1A patent/CN113874014A/zh active Pending
- 2020-05-13 WO PCT/US2020/032725 patent/WO2020232156A1/en not_active Ceased
- 2020-05-13 TW TW109115899A patent/TW202108561A/zh unknown
-
2021
- 2021-11-11 IL IL288034A patent/IL288034B2/en unknown
-
2026
- 2026-03-12 US US19/565,114 patent/US20260200884A1/en active Pending
- 2026-03-23 AU AU2026202224A patent/AU2026202224A1/en active Pending